LONDON--(BUSINESS WIRE)--The global bleeding disorders therapeutics market is expected to grow by USD 4.32 billion as per Technavio. This marks a significant market slowdown compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. However, healthy growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of almost 7%.
Request challenges and opportunities that influence COVID-19 pandemic - Request free sample pages of the bleeding disorders therapeutics market
Read the 120-page report with TOC on "Bleeding Disorders Therapeutics Market Analysis Report by Type (Hemophilia A, Hemophilia B, Von Willebrand disease, and Other disorders), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2020-2024".
The market is driven by rising initiatives to increase awareness. In addition, the R&D of novel therapies is anticipated to boost the growth of the bleeding disorders therapeutics market.
Private and government organizations across the world are undertaking various initiatives to create awareness about the availability of medicines for bleeding disorders. For instance, the World Federation of Hemophilia marked April 27th as the World Hemophilia Day. In 2019, during this initiative, the organization conducted several educational events and regional workshops to create awareness about bleeding disorders through media coverage and training programs. Many such awareness programs and campaigns are leading to the demand for bleeding disorder therapeutics, thereby driving the growth of the market.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Bleeding Disorders Therapeutics Companies:
Baxter International Inc.
Baxter International Inc. operates its business through segments such as Renal care, Medication Delivery, Pharmaceuticals, Advanced surgery, Acute therapies, and Other. Some of the key offerings of the company include FEIBA, HEMOFIL M, RIXUBIS, and Prothromplex TOTAL.
Bayer AG operates its business through segments such as Pharmaceuticals, Crop science, Consumer health, and Animal health. Some of the key offerings of the company include Jivi, KOVALTRY, and Kogenate FS.
CSL Ltd. operates its business through segments such as CSL Behring and Seqirus. Corifact, RiaSTAP, Stimate, Humate-P, AFSTYLA, IDELVION, and MONONINE are some of its key offerings.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. operates its business through segments such as Pharmaceuticals and Diagnostics. HEMLIBRA is one of its key offerings. It is a prophylactic treatment for patients with hemophilia A with or without factor VIII inhibitors.
Grifols SA operates its business through segments such as Bioscience, Hospital, Diagnostic, Bio-supplies, and Others. ALPHANATE, Profilnine SD, and AlphaNine SD are some of its key offerings.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Bleeding Disorders Therapeutics Type Outlook (Revenue, USD Billion, 2020-2024)
- Hemophilia A
- Hemophilia B
- Von Willebrand disease
- Other disorders
Bleeding Disorders Therapeutics Regional Outlook (Revenue, USD Billion, 2020-2024)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Healthcare Include:
Global Hemophilia Therapeutics Market – Global hemophilia market by type (hemophilia A, hemophilia B, and hemophilia C) and geography (North America, Europe, Asia, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.